Public Health: The Health Bureau says it is monitoring about 23,000 chronic hepatitis B patients, with expanded screening for HBsAg now covering more people aged 40+ who have never tested, as Macau remains a “moderate prevalence” area. Infectious Disease Watch: Hong Kong’s Centre for Health Protection is investigating a human infection of rat hepatitis E virus in a 72-year-old man with weakened immunity; officials urge hygiene and stronger rodent prevention. Food Safety: Macau’s Municipal Affairs Bureau found excessive sulphur dioxide in a batch of “Hak San Fried Noodles,” ordering retailers to pull the product and requiring the maker to fix production before follow-up checks. Heat Safety: The Department of Health reminds residents to prevent heat cramps, exhaustion and heat stroke with hydration, light clothing, ventilation, and avoiding strenuous outdoor activity during peak heat. Local Wellness Tech: St Magdalene School, with MPU and an AI tech partner, launched Macau’s first AI-powered exercise and health classroom using smart bikes and questionnaires to generate supervised, personalised exercise plans for students. Cross-border Health & Compliance: Gongbei Customs seized 600 tirzepatide slimming vials at the Zhuhai port of the ZHMB, warning that injectable medical devices need proper registration and labelling before import. Aging & Rehab Services: Two cross-department coordination groups have been set up to drive Macau’s 10-year elderly protection and 10-year rehabilitation action plans from 2026 to 2035. Inclusive Care: Galaxy Macau’s Galaxy Hotel and Galaxy Kidz Edutainment Center have earned Certified Autism Center™ designation, with staff autism training aimed at better supporting sensory-sensitive guests. Medical Innovation Links: Hengqin-Macao cooperation continues to expand, including medical innovation and robotics-linked biotech development in the cooperation zone. Health Tech in the Wider Region: Spero Therapeutics and Innovent Biologics announced an exclusive license for SP001 (IBI355), setting up Phase 2 plans in IgG4-related disease and Sjögren’s disease.